Literature DB >> 32755805

In vitro activity of plazomicin compared to other clinically relevant aminoglycosides in carbapenem-resistant Enterobacteriaceae.

Justin A Clark1, Brandon Kulengowski2, David S Burgess3.   

Abstract

We evaluated the in vitro activity of plazomicin against other aminoglycosides in 122 clinical carbapenem-resistant Enterobacteriaceae isolates using several clinical susceptibility breakpoints. Plazomicin had excellent in vitro activity with 98% overall susceptibility. Amikacin was the next most active with 86% overall susceptibility. This dropped to 55% when switching from Clinical Laboratory and Standards Institute to US Committee on Antimicrobial Susceptibility Testing breakpoints.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Aminoglycoside resistance; Carbapenem-resistant Enterobacteriaceae; Plazomicin; Susceptibility testing

Mesh：

Substances：

Year:  2020        PMID： 32755805     DOI： 10.1016/j.diagmicrobio.2020.115117

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN： 0732-8893            Impact factor:   2.803


  6 in total

Review 1.  Antimicrobial Treatment Options for Difficult-to-Treat Resistant Gram-Negative Bacteria Causing Cystitis, Pyelonephritis, and Prostatitis: A Narrative Review.

Authors:  Andrew Chou; Elwyn Welch; Andrew Hunter; Barbara W Trautner
Journal:  Drugs       Date:  2022-03-14       Impact factor: 11.431

2.  Comparative activity of plazomicin against extended-spectrum cephalosporin-resistant Escherichia coli clinical isolates (2012-2017) in relation to phylogenetic background, sequence type 131 subclones, blaCTX-M genotype, and resistance to comparator agents.

Authors:  Brian D Johnston; Paul Thuras; Stephen B Porter; Connie Clabots; James R Johnson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2021-04-23       Impact factor: 5.103

Review 3.  Therapeutic Options for Metallo-β-Lactamase-Producing Enterobacterales.

Authors:  Xing Tan; Hwan Seung Kim; Kimberly Baugh; Yanqin Huang; Neeraja Kadiyala; Marisol Wences; Nidhi Singh; Eric Wenzler; Zackery P Bulman
Journal:  Infect Drug Resist       Date:  2021-01-18       Impact factor: 4.003

4.  Multicenter Clinical Evaluation of ETEST Plazomicin (PLZ) for Susceptibility Testing of Enterobacterales.

Authors:  Laurine S Blanchard; Alex Van Belkum; Dominique Dechaume; Thomas P Armstrong; Christopher L Emery; Yun X Ying; Michael Kresken; Marion Pompilio; Diane Halimi; Gilles Zambardi
Journal:  J Clin Microbiol       Date:  2021-11-10       Impact factor: 5.948

Review 5.  Efficacy and Safety of Plazomicin in the Treatment of Enterobacterales Infections: A Meta-analysis of Randomized Controlled Trials.

Authors:  Kaicheng Yan; Beibei Liang; Guanxuanzi Zhang; Jin Wang; Man Zhu; Yun Cai
Journal:  Open Forum Infect Dis       Date:  2022-08-29       Impact factor: 4.423

Review 6.  Present and Future Perspectives on Therapeutic Options for Carbapenemase-Producing Enterobacterales Infections.

Authors:  Corneliu Ovidiu Vrancianu; Elena Georgiana Dobre; Irina Gheorghe; Ilda Barbu; Roxana Elena Cristian; Mariana Carmen Chifiriuc
Journal:  Microorganisms       Date:  2021-03-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.